What Researchers Did
Researchers conducted a narrative review of literature and international guidelines to assess the efficacy and tolerance of intravesical treatments for inflammatory and sensory chronic bladder diseases, focusing on agents available in France.
What They Found
The review found that dimethylsulfoxide and glycosaminoglycans, the only intravesical agents available in France, showed promising results. Response rates reached up to 95% and 84% for bladder pain syndrome, while glycosaminoglycans decreased annual cystitis by 2.56 and increased time to recurrence by 130 days in urinary tract infections. In radiation cystitis, these treatments reduced pain by 1.31 and voiding frequency by 1.5 per day at 12 months (P<0.01).
What This Means for Canadian Patients
Canadian patients suffering from chronic inflammatory and sensory bladder diseases might benefit from intravesical treatments as an alternative option, especially when other therapies are limited. However, patients should be aware that these treatments can be costly and their long-term effectiveness may vary.
Canadian Relevance
This study specifically reviewed agents available in France and did not include any Canadian data or context. Therefore, its direct Canadian relevance is limited.
Study Limitations
A significant limitation of this review is the low level of evidence found in the existing literature regarding the efficacy and certainty of outcomes for these intravesical treatments.